V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330011763 | 330011879 | 1.75 | null | Palliative (P) | 2016-11-11 | 2016-11-12 | Etoposide oral | N | N | 330018009 | ETOPOSIDE |
| 330011764 | 330005226 | 1.6 | 23 | Neo-adjuvant (N) | 2017-11-04 | 2017-11-04 | GemCarbo Days 1+8 | N | N | 330018021 | GEMCARBO |
| 330011765 | 330005230 | 0 | null | Disease modification (D) | 2013-12-30 | 2014-01-04 | NIVOLUMAB | null | N | 330018074 | AZACITIDINE |
| 330011766 | 330005234 | 0 | 40.9 | Neo-adjuvant (N) | 2015-09-28 | 2015-09-28 | NIVOLUMAB | 02 | N | 330018155 | CYCLOPHOSPHAMIDE + TOPOTECAN |
| 330011767 | 330005245 | 1.7 | null | Palliative (P) | 2016-04-09 | 2016-04-09 | VAC | 2 | N | 330018401 | CISPLATIN + ETOPOSIDE |
| 330011768 | 330008864 | 1.65 | 66.9 | Palliative (P) | 2014-03-15 | 2014-05-21 | Cisplatin + Doxorubicin | 02 | Y | 330018542 | VINBLASTINE |
| 330011769 | 330005258 | 1.46 | 65.8 | Curative (C) | 2014-08-19 | 2014-10-05 | NIVOLUMAB | N | N | 330018671 | CISPLATIN + ETOPOSIDE |
| 330011770 | 330005260 | 1.8 | null | Curative (C) | 2018-03-12 | 2018-07-05 | Cisplatin + Doxorubicin | null | N | 330018694 | NIVOLUMAB |
| 330011771 | 330008870 | 1.69 | null | Curative (C) | 2013-02-08 | 2014-03-12 | EURO-EWING | 02 | N | 330018705 | EURO-EWING |
| 330011772 | 330005268 | null | null | Curative (C) | 2017-12-06 | 2018-01-17 | Methotrexate intrathecal | N | N | 330018777 | METHOTREXATE INTRATHECAL |
| 330011774 | 330008876 | 1.81 | 87.7 | Palliative (P) | 2016-08-18 | 2016-08-18 | EW EuroEwing 99 : VIDE | N | N | 330018883 | EURO-EWING |
| 330011775 | 330005283 | 1.66 | 20.4 | Palliative (P) | 2014-12-12 | 2014-12-12 | CNS HGG Temozolomide maintenance | 2 | N | 330018906 | AZACITIDINE |
| 330011776 | 330008877 | 1.79 | 71.8 | Palliative (P) | 2016-04-12 | 2016-05-05 | FLAG + Idarubicin | N | N | 330018923 | FLAG + IDARUBICIN |
| 330011777 | 330005288 | 0 | null | Curative (C) | 2017-12-29 | 2017-12-30 | FLAG + Idarubicin | 02 | N | 330018945 | FLAG + IDARUBICIN |
| 330011778 | 330005292 | 0 | null | Palliative (P) | 2016-05-14 | 2016-05-15 | FLAG + Idarubicin | 02 | N | 330018990 | FLAG + IDARUBICIN |
| 330011779 | 330008885 | 1.76 | 66.8 | Palliative (P) | 2018-06-27 | 2018-06-27 | FLAG + Idarubicin | 2 | N | 330019079 | FLAG + IDARUBICIN |
| 330011780 | 330005302 | 1.68 | 89.4 | Neo-adjuvant (N) | 2014-03-07 | 2014-03-16 | DA 3+8 | N | N | 330019100 | CYCLOPHOSPHAMIDE + TOPOTECAN |
| 330011781 | 330005303 | null | 47 | Palliative (P) | 2015-07-15 | 2015-10-17 | CISPLATIN + ETOPOSIDE | null | null | 330019112 | AZACITIDINE |
| 330011782 | 330005307 | 0 | 74.2 | Adjuvant (A) | 2016-09-19 | 2016-09-24 | Azacitidine | N | N | 330019124 | CISPLATIN + DOXORUBICIN |
| 330011783 | 330005309 | 1.8 | null | Palliative (P) | 2018-12-21 | 2018-12-21 | CARBOPLATIN + GEMCITABINE | 2 | N | 330019291 | GEMCARBO |
| 330011784 | 330011890 | 1.63 | 61 | Palliative (P) | 2015-02-05 | 2015-08-05 | Cytarabine High Dose | Y | N | 330019369 | CYTARABINE HIGH DOSE |
| 330011786 | 330005317 | 1.58 | 11.5 | Palliative (P) | 2016-09-15 | 2017-01-22 | Methotrexate intrathecal | N | N | 330019489 | METHOTREXATE INTRATHECAL |
| 330011787 | 330011894 | 1.85 | null | Palliative (P) | 2014-02-04 | 2014-03-16 | Azacitidine | 2 | Y | 330019528 | CYCLOPHOSPHAMIDE + TOPOTECAN |
| 330011788 | 330008902 | null | 93 | Curative (C) | 2013-04-10 | 2013-04-10 | Cisplatin + Etoposide (3 day) | 02 | N | 330019584 | CISPLATIN + ETOPOSIDE |
| 330011790 | 330005332 | 1.66 | 89.7 | Disease modification (D) | 2017-12-25 | 2017-12-29 | Cisplatin + Etoposide (5 day) | N | N | 330019614 | CISPLATIN + ETOPOSIDE |
| 330011791 | 330012855 | null | 45.1 | Palliative (P) | 2016-06-02 | 2017-08-17 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | null | 330019616 | DHAP |
| 330011792 | 330005335 | 1.62 | null | Disease modification (D) | 2015-04-04 | 2015-04-07 | CLOFARABINE + CYCLO + CYTARABINE + ETOP | N | null | 330019624 | LENALIDOMIDE |
| 330011793 | 330010831 | 1.7 | 55.9 | Curative (C) | null | 2016-10-29 | Ifosfamide | Y | N | 330019626 | MITOTANE |
| 330011794 | 330005338 | null | 85.1 | Adjuvant (A) | 2015-11-30 | 2015-11-30 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 2 | null | 330019627 | IRINOTECAN + VINCRISTINE |
| 330011795 | 330005340 | 1.95 | null | Curative (C) | 2015-12-21 | 2016-01-16 | PEI | N | null | 330019639 | BLEOMYCIN + VINCRISTINE |
| 330011796 | 330005343 | null | 63.6 | Adjuvant (A) | 2018-01-13 | 2018-05-21 | Ifosfamide | N | null | 330019654 | ATG + BUSULFAN + FLUDARABINE |
| 330011797 | 330008914 | 1.74 | 82 | Curative (C) | 2013-09-30 | 2014-01-14 | Capecitabine (14 days)+Carboplatin | N | N | 330019674 | CETUXIMAB + CISPLATIN + FU |
| 330011798 | 330005349 | 1.77 | 74.6 | Palliative (P) | 2015-08-08 | 2015-08-09 | Cetuximab + CISPLATIN + FLUOROURACIL | N | N | 330019675 | CARBOPLATIN + CETUXIMAB + FU |
| 330011800 | 330008921 | 1.79 | 69 | Palliative (P) | null | 2015-12-18 | LOMUSTINE + PROCARBAZINE | N | null | 330019771 | DOXORUBICIN + HD MTX |
| 330011801 | 330008924 | null | 44 | Curative (C) | 2013-06-21 | 2013-07-20 | EMA/CO | null | null | 330019784 | EC |
| 330011802 | 330010838 | 1.72 | 60.4 | Curative (C) | null | 2017-09-19 | ALL UKALL2011 TRIAL | null | null | 330019806 | CETUXIMAB + CISPLATIN + FU |
| 330011803 | 330005369 | 1.75 | 78.9 | Palliative (P) | null | 2015-02-12 | Cyclophosphamide High Dose | Y | null | 330019807 | EMA/CO |
| 330011804 | 330005377 | 1.79 | 39.2 | Palliative (P) | 2014-04-01 | 2014-04-10 | Bevacizumab 7.5mg/kg | N | null | 330019906 | IRINOTECAN + MDG |
| 330011805 | 330005383 | null | null | Neo-adjuvant (N) | 2013-04-18 | 2013-12-19 | Cyclophosphamide + Vincristine | Y | N | 330019921 | EDP + MITOTANE |
| 330011806 | 330005386 | 1.68 | 90.6 | Palliative (P) | 2013-12-01 | 2014-01-07 | Carboplatin + Cetux + FU (>Cycle 2) | 02 | N | 330019979 | PEMBROLIZUMAB |
| 330011807 | 330011904 | 1.73 | 59.95 | Curative (C) | 2016-02-12 | 2016-03-28 | IBRUTINIB | null | N | 330020045 | MITOTANE |
| 330011808 | 330005396 | 1.84 | 120.1 | Curative (C) | 2017-07-16 | 2018-01-23 | CNS LGG Irinotecan & Bevacizumab | N | N | 330020121 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330011809 | 330005400 | null | 61.85 | Adjuvant (A) | 2016-05-17 | 2017-02-12 | MA (Cytarabine 3g/m2) | N | null | 330020140 | BORTEZOMIB |
| 330011810 | 330008942 | 0 | null | null | null | 2018-05-03 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | null | 330020153 | UKALL XII |
| 330011811 | 330005406 | null | 54.5 | Palliative (P) | 2015-05-02 | 2015-05-02 | Cyclophosphamide + Vincristine | Y | N | 330020179 | IFOSFAMIDE |
| 330011812 | 330005409 | 1.57 | 62 | Neo-adjuvant (N) | 2015-11-29 | 2016-01-02 | EMA/CO | 2 | N | 330020208 | IFOSFAMIDE |
| 330011813 | 330008950 | 1.82 | 76.8 | Adjuvant (A) | 2016-05-18 | 2016-05-22 | VINCRISTINE | 2 | N | 330020223 | VIDE |
| 330011814 | 330011907 | 1.64 | 69 | Palliative (P) | 2015-03-09 | 2015-07-21 | Trastuzumab Subcutaneous | N | N | 330020236 | VIDE |
| 330011815 | 330005415 | 1.7 | 87.75 | Neo-adjuvant (N) | 2014-02-16 | 2016-04-26 | Bevacizumab 15mg/kg | N | N | 330020254 | GEMCITABINE + PACLITAXEL |
| 330011817 | 330008957 | 1.75 | 74.6 | Curative (C) | 2017-11-30 | 2018-08-08 | DHAP | N | N | 330020306 | HYDROXYCARBAMIDE |